{"disease":{"id":"dyslipidemia","name":"Dyslipidemia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":16},"drugs":{"marketed":[{"drug_id":"evolocumab","indication_name":"Complex dyslipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Repatha","generic_name":"EVOLOCUMAB","company_name":"Repatha","drug_phase":"marketed","molecular_target":"PCSK9","drug_class":"PCSK9 Inhibitor [EPC]","quality_score":75,"revenue":"2100","mechanism":"Evolocumab, a human monoclonal IgG2, lowers LDL-C by inhibiting PCSK9 binding to LDLR, increasing LDLR availability to clear LDL."},{"drug_id":"alirocumab","indication_name":"Complex dyslipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Praluent","generic_name":"ALIROCUMAB","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Proprotein convertase subtilisin/kexin type 9","drug_class":"PCSK9 Inhibitor [EPC]","quality_score":62,"revenue":"857","mechanism":"Praluent blocks the PCSK9 protein, which helps remove LDL cholesterol from the bloodstream, thereby reducing cholesterol levels."},{"drug_id":"laropiprant","indication_name":"Dyslipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"LAROPIPRANT","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin D2 receptor","drug_class":"laropiprant","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"saroglitazar","indication_name":"Diabetic dyslipidemia associated with type 2 diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipaglyn","generic_name":"SAROGLITAZAR","company_name":"Cadila Healthcare","drug_phase":"marketed","molecular_target":"Peroxisome proliferator-activated receptor alpha","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"praluent","indication_name":"Complex dyslipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Praluent","company_name":"Regeneron Pharmaceuticals","drug_phase":"marketed","molecular_target":"Proprotein convertase subtilisin/kexin type 9","drug_class":"","quality_score":16,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03847753","title":"Exploring the Comorbidity Between Mental Disorders and General Medical Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":5940299,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT05221528","title":"Association Between Lipid Profiles and Cardiovascular Events","phase":"","overall_status":"UNKNOWN","enrollment_count":4234339,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT05285085","title":"Real World Evidence Study of Statin Use in Brazil","phase":"","overall_status":"COMPLETED","enrollment_count":2133900,"lead_sponsor_name":"Hospital Israelita Albert Einstein","has_results":false},{"nct_id":"NCT04067297","title":"Using Big Data to Conduct Innovative Cardiovascular Clinical Trials","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500000,"lead_sponsor_name":"Institute for Clinical Evaluative Sciences","has_results":false},{"nct_id":"NCT06622304","title":"Exploring the Effects of Antihypertensive and Lipid-Lowering Drugs on Inflammatory Cytokine Levels","phase":"","overall_status":"COMPLETED","enrollment_count":250736,"lead_sponsor_name":"Guangzhou Institute of Respiratory Disease","has_results":false},{"nct_id":"NCT01764633","title":"Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":27564,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT07308314","title":"Taining Golden Lake Comprehensive Chronic Disease Management Initiative","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"First Affiliated Hospital of Fujian Medical University","has_results":false},{"nct_id":"NCT05614765","title":"Evaluation of Dyslipidemia Management After Statin and Ezetimibe Complex Treatment","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":18000,"lead_sponsor_name":"Daewoong Pharmaceutical Co. LTD.","has_results":false},{"nct_id":"NCT05889143","title":"A Study to Evaluate the Efficacy and Safety of CREZET Tablet","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Daewoong Pharmaceutical Co. LTD.","has_results":false},{"nct_id":"NCT03799185","title":"Dyslipidemia Prevalence, Perception, Treatment, and Awareness in the Tunisian Population","phase":"","overall_status":"COMPLETED","enrollment_count":13610,"lead_sponsor_name":"Association Tunisienne d'Etude & de Recherche sur l'Athérosclérose","has_results":false},{"nct_id":"NCT05542719","title":"Mexican Registry of Dyslipidemia in Patients at High Risk and Very High Risk of Atherosclerotic Cardiovascular","phase":"","overall_status":"UNKNOWN","enrollment_count":13166,"lead_sponsor_name":"Coordinación de Investigación en Salud, Mexico","has_results":false},{"nct_id":"NCT07515560","title":"Efficacy and Safety of Baroezet Tablet in Korean Patients With Dyslipidemia: A Prospective Observational Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Daewoong Pharmaceutical Co. LTD.","has_results":false},{"nct_id":"NCT07409636","title":"A Study to Assess the Real-World Effectiveness of Inclisiran and PCSK9 mAbs in Chinese Hypercholesterolemia Adult Patients","phase":"","overall_status":"COMPLETED","enrollment_count":11991,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02835287","title":"Diabetes Complication Control in Community Clinics (D4C) Trial","phase":"NA","overall_status":"UNKNOWN","enrollment_count":11132,"lead_sponsor_name":"Tulane University","has_results":false},{"nct_id":"NCT04554953","title":"A Combination Drug Including Fimasartan and Statins in Patients With Hypertension and Dyslipidemia","phase":"","overall_status":"COMPLETED","enrollment_count":10877,"lead_sponsor_name":"Boryung Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT03071692","title":"Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":10544,"lead_sponsor_name":"Kowa Research Institute, Inc.","has_results":true},{"nct_id":"NCT03418974","title":"Safety and Efficacy of Statins for Chinese Patients With Dyslipidemia","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04271280","title":"Treatment of High and Very High riSk Dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events","phase":"","overall_status":"COMPLETED","enrollment_count":9559,"lead_sponsor_name":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","has_results":true},{"nct_id":"NCT06115213","title":"The North Kynouria Project","phase":"NA","overall_status":"UNKNOWN","enrollment_count":7000,"lead_sponsor_name":"University Hospital, Ioannina","has_results":false},{"nct_id":"NCT06186037","title":"Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":6356,"lead_sponsor_name":"Saint Vincent's Hospital, Korea","has_results":false},{"nct_id":"NCT02991534","title":"Cardiovascular Risk Screening and Risk Reduction in Women Vets","phase":"NA","overall_status":"COMPLETED","enrollment_count":6009,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT05845424","title":"High-intensity Statin and Ezetimibe Therapy for Asymptomatic Patients With Positive Coronary Calcium","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT07350486","title":"LLM-CoManage: Large Language Model-Enabled Co-Management of Hypertension, Diabetes, and Dyslipidemia","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":6000,"lead_sponsor_name":"First Hospital of China Medical University","has_results":false},{"nct_id":"NCT04829149","title":"Statin Monotherapy and Rosuzet Tab.(Rosuvastatin/Ezetimibe) Administration in Patients With Dyslipidemia in Korea","phase":"","overall_status":"COMPLETED","enrollment_count":5717,"lead_sponsor_name":"Hanmi Pharmaceutical Company Limited","has_results":false},{"nct_id":"NCT05184179","title":"Observational Study to Evaluate the Therapeutic Effectiveness and Safety of Olomax Tab","phase":"","overall_status":"COMPLETED","enrollment_count":5450,"lead_sponsor_name":"Daewoong Pharmaceutical Co. LTD.","has_results":false},{"nct_id":"NCT05450575","title":"An Observational Study to Evaluate Effectiveness and Safety of Amosartan Q Tablet","phase":"","overall_status":"COMPLETED","enrollment_count":5400,"lead_sponsor_name":"Hanmi Pharmaceutical Company Limited","has_results":false},{"nct_id":"NCT02867813","title":"Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":5035,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT02993120","title":"Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":5006,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT04579367","title":"Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","has_results":false},{"nct_id":"NCT03939039","title":"From Known to New Genes in Dyslipidemia","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT03329729","title":"PLATOREL® STUDY IN CARDIOVASCULAR RISΚ ASSESMENT","phase":"","overall_status":"COMPLETED","enrollment_count":4700,"lead_sponsor_name":"Elpen Pharmaceutical Co. Inc.","has_results":false},{"nct_id":"NCT06258005","title":"PocDoc Lipids Out-of-Surgery Study","phase":"","overall_status":"COMPLETED","enrollment_count":4256,"lead_sponsor_name":"Vital Signs Solutions Ltd","has_results":false},{"nct_id":"NCT05039034","title":"Screening and Management of High-risk Populations of Stroke in Dehui City","phase":"","overall_status":"COMPLETED","enrollment_count":4100,"lead_sponsor_name":"Yi Yang","has_results":false},{"nct_id":"NCT07043166","title":"Cardiovascular-Kidney-Metabolic Syndrome in Shanghai Zicitizens","phase":"","overall_status":"RECRUITING","enrollment_count":4094,"lead_sponsor_name":"Shanghai Changzheng Hospital","has_results":false},{"nct_id":"NCT06204380","title":"An Observational Study on the Identification of Prescription Patterns of STAFEN Cap","phase":"","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"Hanlim Pharm. Co., Ltd.","has_results":false},{"nct_id":"NCT05660135","title":"Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":4000,"lead_sponsor_name":"Daewoong Pharmaceutical Co. LTD.","has_results":false},{"nct_id":"NCT06293417","title":"To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM","phase":"NA","overall_status":"RECRUITING","enrollment_count":3958,"lead_sponsor_name":"Korea University Anam Hospital","has_results":false},{"nct_id":"NCT01854918","title":"Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3681,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT07468500","title":"Real World Adherence of PCSK9 Targeted Therapy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3600,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT01414192","title":"A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204)","phase":"","overall_status":"COMPLETED","enrollment_count":3215,"lead_sponsor_name":"Organon and Co","has_results":true},{"nct_id":"NCT03214211","title":"Prospective Observational Study of Pravafenix Cap","phase":"","overall_status":"UNKNOWN","enrollment_count":3088,"lead_sponsor_name":"Yooyoung Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05120895","title":"An Observational Study Investigating the Change in Blood Cholesterol With Mevalotin® Tablet Administration in Korean Menopausal Women Aged 50 Years or More Who Require Treatment of Dyslipidemia","phase":"","overall_status":"COMPLETED","enrollment_count":3060,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT03892265","title":"A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3005,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":false},{"nct_id":"NCT06866509","title":"To Investigate Blood Lipid Changes and Safety After Litorvazet® Tablets in Dyslipidemia Patients","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"Daewoong Pharmaceutical Co. LTD.","has_results":false},{"nct_id":"NCT05117424","title":"CArdioMetabolism and Atherosclerotic PlaqUe progreSsion","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT05107063","title":"An Observational Study Investigating the Effectiveness of Pravastatin on Renal Function in Korean Dyslipidemic Patients With Type 2 Diabetes","phase":"","overall_status":"COMPLETED","enrollment_count":2972,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT04015726","title":"Secular Trends in the Prevalence of Cardiometabolic Risk Factors Among Teenage School Children in Urban South India","phase":"","overall_status":"UNKNOWN","enrollment_count":2815,"lead_sponsor_name":"India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals","has_results":false},{"nct_id":"NCT07206472","title":"A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2560,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT05142722","title":"Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2530,"lead_sponsor_name":"NewAmsterdam Pharma","has_results":true},{"nct_id":"NCT03861533","title":"GOAL International QuERI - Protocol CHRC 2019 GOAL INTERNATIONAL","phase":"","overall_status":"COMPLETED","enrollment_count":2422,"lead_sponsor_name":"Dr. Anatoly Langer","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}